Abstract:Cadaveric islet and stem cell-derived transplantations hold promise as treatments for type 1 diabetes. To tackle the issue of immunocompatibility, numerous cellular macroencapsulation techniques have been developed that utilize diffusion to transport insulin across an immunoisolating barrier. However, despite several devices progressing to human clinical trials, none have successfully managed to attain physiologic glucose control or insulin independence. Based on empirical evidence, macroencapsulation methods with multilayered, high islet surface density are incompatible with homeostatic, on-demand insulin delivery and physiologic glucose regulation, when reliant solely on diffusion. An additional driving force is essential to overcome the distance limit of diffusion. In this study, we present both theoretical proof and experimental validation that applying pressure at levels comparable to physiological diastolic blood pressure significantly enhances insulin flux across immunoisolation membranes, increasing it by nearly three orders of magnitude. This significant enhancement in transport rate allows for precise, sub-minute regulation of both bolus and basal insulin delivery. By incorporating this technique with a pump-based extravascular system, we demonstrate the ability to rapidly reduce glucose levels in diabetic rodent models, effectively replicating the timescale and therapeutic effect of subcutaneous insulin injection or infusion. This advance provides a potential path towards achieving insulin independence with islet macroencapsulation.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to achieve more effective blood - glucose control by improving the transmission efficiency of insulin during the macro - encapsulation of islet cells for the treatment of type 1 diabetes. Specifically, the paper explores whether the application of sub - minute pressure at the physiological level can significantly enhance the transmission rate of insulin from macro - encapsulated islet cells, thereby achieving faster and more accurate insulin delivery, so as to achieve an effect similar to that of subcutaneous injection or infusion of insulin. ### Background and Problems of the Paper 1. **Current Situation of Type 1 Diabetes Treatment** - The current main treatment method is through subcutaneous injection or infusion of exogenous insulin. - Although the automated insulin delivery (AID) system is becoming more and more common, its effectiveness and penetration rate are still limited, especially among ethnic minorities. - The treatment burden is heavy, the cost is high, and there is a risk of acute hypoglycemia. 2. **Challenges of Islet Transplantation** - Islet transplantation can reduce the management and economic burden on patients, but the problem of immune rejection limits its wide application. - Encapsulation technologies (nano - and micro - encapsulation) have improved cell survival rates, but it is difficult to achieve complete immune isolation and difficult to retrieve. - Although the macro - encapsulation device provides immune isolation and retrievability, due to its reliance on diffusive transport of insulin and oxygen, the surface density of islets is limited, and physiological blood - glucose control cannot be achieved. 3. **Limitations of Diffusive Transport** - The time for diffusive transport of insulin is long. It usually takes more than 10 minutes to transport 90% of insulin, which does not meet physiological needs. - In order to increase the surface density of islets, it is necessary to increase the thickness of the implant, which further prolongs the diffusion time and makes diffusive transport impractical. ### Core Problem of the Paper The core problem of the paper is to explore a new method. By applying short - time pressure at the physiological level, overcome the limitations of diffusive transport, significantly improve the transmission rate of insulin, thereby achieving rapid and accurate insulin delivery, and finally achieving physiological blood - glucose control. ### Solutions 1. **Theoretical Analysis** - Through theoretical analysis, the author found that the application of pressure can significantly improve the transmission rate of insulin. Specifically, the application of a pressure of 10 kPa (close to the diastolic blood pressure of normal people) can increase the transmission rate of insulin by nearly three orders of magnitude. 2. **Experimental Verification** - Through numerical simulation and experimental research, the author verified the results of theoretical analysis. The results showed that the application of a pressure of 11 kPa can complete the transmission of insulin within a few seconds, while it takes several hours by diffusion alone. - Further in - vitro experiments showed that the application of short - time pressure can achieve repeated insulin pulse delivery without affecting the health and function of β - cells. 3. **In - vivo Verification** - Through in - vivo experiments in wild - type mice and STZ - induced diabetic mice, the author proved that the application of short - time pressure can significantly increase the blood insulin level, rapidly reduce the blood - glucose level, and achieve physiological blood - glucose control. - Using a wireless wearable micropump system, repeated insulin pulse delivery in freely moving mice was achieved, further verifying the feasibility and effectiveness of this method. In conclusion, through theoretical analysis and experimental verification, this paper proposes a new method, that is, applying short - time pressure at the physiological level, which significantly improves the transmission rate of insulin and provides new ideas for more effective treatment of type 1 diabetes.

Enhancing Therapeutic Insulin Transport from Macroencapsulated Islets Using Sub-Minute Pressure at Physiological Levels